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Genetic Basis of Diabetic Nephropathy
It is well known that all patients with Type 2 Diabetes Mellitus (T2DM) do not develop chronic kidney 
disease (CKD). Several metabolic, hemodynamic and intracellular mechanisms have been proposed to 
play role in the pathogenesis of Diabetic Nephropathy (DN).  Clustering of patients with DN in certain 
ethnic groups and families suggests the role of genetic factors.  We have studied various facets about 
genetic determinants which may inﬂuence the development of kidney disease in patients with T2DM.
We have found that Angiotensin Converting Enzyme (ACE) DD genotype conferred the maximum 
risk, whereas ACE II genotype seemed to confer protective role against development of diabetic and 
nondiabetic CKD. Further, we found that oxidative stress (OS) plays a signiﬁcant role in the 
development of DN and that Glutathione S-transferase theta-1and/or Glutathione S-transferase Mu-1 
null genotypes are associated with higher OS in patients with DN. In addition, we also found that 
increased levels of inﬂammatory mediators, i.e. Tumor necrosis factor-α (TNF-α), high-sensitivity C-
reactive protein (hsCRP) and Urinary Monocyte Chemoattractant Protein-1 (uMCP-1) play a 
signiﬁcant role in contributing to OS. We have shown that genetic polymorphism of NF-kB gene and 
TNF-α gene plays a role in determining serum level of various inﬂammatory markers and oxidant 
stress parameters. We found signiﬁcant association of -429T/C and Gly82Ser Receptors for Advanced 
Glycation End-products (RAGE) polymorphisms with the development of macrovascular and 
microvascular complications, respectively in T2DM subjects.  Further, we have observed that AGE-
mediated exacerbation of RAGE expression may play a role in pathogenesis of various vascular 
complications in T2DM.
To conclude, polymorphisms of various genes involved in renin-angiotensin aldosterone system 
(RAAS), inﬂammatory, oxidant stress, cytoprotective and nitrous oxide pathways and enhanced 
RAGE mRNA expression may adversely inﬂuence ﬁnal common pathway through oxidant stress 
mechanisms, and inﬂuence the levels of various cytokines and intracellular signaling mechanisms, 
thereby inﬂuencing the susceptibility of patients with diabetes mellitus for development of kidney 
disease and vascular complications.
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ABSTRACT
Introduction 
 Diabetes Mellitus (DM) has become a 
leading cause of morbidity and mortality and is 
considered a major public health problem that 
places a signiﬁcant burden on global healthcare 
resources. It is, however, much less appreciated 
that the diabetes epidemic would also be 
accompanied by an epidemic of Chronic Kidney 
Disease (CKD), which brings with it a huge 
burden of Cardiovascular Disease (CVD) and 
End-stage Renal Disease (ESRD), leading to 
premature death. It is estimated that the number 
of people with diabetes will rise from 171 
million in 2000 to 366 million in 2030, resulting 
in millions of new cases of CKD, most of them 
b e i n g  i n  t h e  d e v e l o p i n g  w o r l d  ( 1 ) . 
Approximately one-fourth to one-third of all 
diabetics go on to develop Diabetic Nephropathy 
(DN), making it one of the leading cause of CKD 
and ESRD requiring renal replacement therapy 
(2,3). Recent data from CKD Registry of India 
shows that DN accounts for the single largest 
group of patients with CKD (4). Since treating 
ESRD is simply unaffordable for most 
developing countries, the emphasis has to be on 
prevention, early detection and slowing of 
progression from early stages of CKD to ESRD. 
 Despite relentless research, the complex 
etiopathogenesis of kidney disease in DM has 
not been fully understood. The pathogenesis of 
DN is clearly multifactorial and several 
metabolic, hemodynamic and intracellular 
mechanisms or factors have been proposed to 
play a role in the onset and progression of disease 
(5), and are currently under active investigation 
at various centres all over the world.  In addition, 
certain hereditary and environmental factors 
have been implicated in the etiopathogenesis of 
DN. During the last few years, we have focused 
our research into various genetic factors which 
may be potentially associated with the 
development of nephropathy in patients with 
Type 2 diabetes mellitus (T2DM).
Predictors for Development of Nephropathy 
in DM 
 There are various factors which play a role 
in the development of nephropathy in DM. The 
most well-known amongst these include poor 
glycemic control, family history of diabetes or 
hypertension, increased activity of sodium-
lithium counter-transport mechanism in red 
blood cells, etc. Of these, most of the studies 
have focused on the role of glycemic control in 
the development of various complications. 
Studies done in Type1diabetes mellitus 
(T1DM), such as Diabetes Control and 
Complications Trial (DCCT) have shown that 
tight glycemic control using multiple insulin 
i n j e c t i o n s  r e d u c e s  t h e  i n c i d e n c e  o f 
microalbuminuria by 39% (6).  Similarly, in 
United Kingdom Prospective Diabetes Study 
(UKPDS), a 30% risk reduction for the 
development of microalbuminuria was observed 
i n  t h e  g r o u p  i n t e n s i v e l y  t r e a t e d  f o r 
hyperglycemia (7). In the Kumamoto Study, 
intensive glycemic control reduced the rate of 
micro- and macroalbuminuria (8). However, it is 
pertinent to note that in these studies several 
patients developed DN despite tight glycemic 
control and vice versa. In a cross-sectional 
survey of 507 patients with T2DM, we found 
that self-efﬁcacy was the single most important 
determinant of current diabetes control (p<0.01) 
and self-efﬁcacy was inﬂuenced by various 
factors, such as educational status, employment, 
family support and mental attitude (9). 
Previously,  i t  was bel ieved that  once 
albuminuria had become persistent, glycemic 
control lost its beneﬁcial effect on the kidney, but 
several recent studies have documented the 
importance of glycemic control on the 
progression of nephropathy in patients with 
T1DM. Among the most important putative 
promoters of progression of kidney disease, 
blood pressure has been documented to have a 
close relation with rate of decline of glomerular 
ﬁltration rate in both T1DM and T2DM. Serum 
cholesterol concentration has been shown to be 
another predictor of progression of nephropathy 
in both types of diabetes. Dietary protein 
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restriction retards the progression of renal 
disease in diabetes while smoking has been 
suggested to play a role in the progression of 
nephropathy in both types of diabetes. 
Hereditary and Ethnic Factors
 Present day knowledge states that speciﬁc 
genetic backgrounds might inﬂuence the 
development of DN. Indeed, only 30% patients 
with T1DM and 40% patients with T2DM 
develop DN irrespective of treatment for 
diabetes (10), and DN often shows a familial 
clustering in siblings with diabetes. It has been 
noted that the prevalence rates of DN in subjects 
with T2DM show a marked ethnic variation. 
Higher rates of diabetic renal disease are seen in 
Indo-Asians in the UK, in African-Americans 
(11), in Nauruans (12) and Pima Indians (13). 
The reason for this inter-racial difference in the 
incidence of DN is unclear, but ethnic variation 
in genetic susceptibility to nephropathy is a 
possibility. It is noteworthy that these ethnic 
groups not only have a very high incidence of 
T2DM,  bu t  a l so  a  h igh  inc idence  o f 
hypertension. This suggests that differences in 
genetic predisposition to hypertension may 
contribute to the higher prevalence of 
nephropathy in certain racial groups; although 
an alternative explanation may be that the 
presence of hypertension may accelerate an 
already present renal disease and lead to the 
condition becoming clinically manifest more 
quickly. 
Rationale for Genetic Studies in DN
 The fact that, a fairly large number of 
patients with DM goes on to develop 
nephropathy even in the absence of various 
factors mentioned above, has led scientists to 
postulate and investigate various genetic factors 
leading to this dreadful complication. There is 
enough evidence supporting the concept of 
genetic susceptibility to nephropathy in patients 
with diabetes (14,15). Discovery of genetic 
variants that underpin susceptibility to 
nephropathy could yield important insights into 
this condition. Firstly, it would permit 
identiﬁcation of patients at risk of nephropathy 
shortly after diagnosis of diabetes rather than 
much later when persistent microalbuminuria 
develops, by which time there is already 
histological evidence of renal injury. This would 
facilitate targeted therapeutic interventions 
aimed at primary prevention rather than 
secondary treatment of established nephropathy. 
Secondly, and perhaps more importantly, if the 
susceptibility variants are located in genes that 
have not previously been implicated in DN, this 
may lead to improved understanding of its 
pathophysiology and development of targeted 
novel therapies. 
Strategies for Identifying Susceptibility  
Genes 
 The etiology of DN is multifactorial, yet 
there is clear evidence of genetic basis. Strong 
association of familial aggregation and the 
heritability of DN in patients with T2DM 
provide compelling evidence that DN and its 
related traits are inﬂuenced by genetic factors 
and suggest a complex, multifactorial mode of 
i n h e r i t a n c e  w i th  o n e  o r  mo r e  ma j o r 
susceptibility genes. Familial clustering of renal 
disease in T2DM supports the hypothesis that 
the increased risk of DN in T2DM is partly due to 
a shared gene or set of genes among affected 
f a m i l y  m e m b e r s  a n d  h a s  m o t i v a t e d 
investigations aimed at identifying the speciﬁc 
chromosomal regions that harbor genes 
contributing to its susceptibility. The major 
approaches that are currently being used to 
identify DN susceptibility genes are: 
(i) Candidate gene approach, (ii) Linkage 
analysis,  and (iii) Genome-wide association 
studies.
The Candidate Gene Approach 
 The candidate gene approach involves 
assessment of genetic variation, typically Single 
Nucleotide Polymorphisms (SNPs) in one or 
more genes with plausible physiological roles in 
DN. These SNPs lie within a candidate gene or 
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region and are selected from the literature or 
from the Hap Map database (www.hapmap.org). 
The goal is to demonstrate a signiﬁcant 
difference in allele frequencies between cases 
with DN and control subjects. In various studies 
done in our laboratory at University College of 
Medical Sciences, Delhi, in the ﬁeld of DN, we 
have followed the candidate gene approach. A 
large number of candidate genes involved in 
several pathways have been tested for 
association with the development and 
progression of DN based on the possible 
physiological role of the genes in patients with 
DM and kidney disease, such as, renin-
angiotensin aldosterone system (RAAS), 
glucose metabolism, growth factors, oxidative 
stress (OS), inﬂammation, lipid metabolism, etc.
 Several candidate gene studies involving 
the above-mentioned genes to study the 
association with DN have been reported; 
however, the results have largely been 
inconsistent. Limitations of this approach 
include that candidate gene studies are 
frequently based on small number of cases and 
controls resulting in underpowered analyses. 
Various meta-analyses are being carried out to 
overcome the limitations of individual candidate 
gene study.  Various candidate genes which we 
have studied belonging to different classes are 
discussed below:
A. Genes Involved in RAAS 
 RAAS has been shown to play a central 
role in the pathogenesis of most forms of CKD. 
Prorenin, renin, Angiotensin-Converting 
Enzyme (ACE) and angiotensin II levels are all 
noted to be elevated in DN (16). Furthermore, 
genes of the RAAS have been suggested as being 
genetic determinants for both hypertension and 
CVD, both of which are common in patients with 
DN. 
 Polymorphism of ACE gene has been 
implicated in determining the blood level of 
ACE and thereby may play an important role in 
the pathogenesis of DN. Initially we did a pilot 
study to investigate the prevalence of 
polymorphisms of ACE genotype in 100 
subjects including patients with T2DM 
with/without DN, patients with non-diabetic 
CKD and healthy controls (17). We found that  
D allele of ACE gene acts as a risk factor for the 
development of nephropathy in patients with 
T2DM as well as for nondiabetic CKD, while    
I allele of ACE gene was protective in nature.
 Few other investigators have studied ACE 
gene insertion-deletion polymorphism in DN 
patients with T2DM (18).  A large meta-analysis 
found the association of ACE D allele with DN 
risk with an odds ratio (OR) in the range of 
1.25–1.57 in the Asian subgroup (19); however, 
no signiﬁcant effects were detected for the 
Caucasian subgroup. In DN, two small studies 
have suggested an association between the       
D allele of the ACE gene and nephropathy 
(20,21); however, other subsequent large studies 
with and without nephropathy have shown no 
association between nephropathy and the         
D allele (22). Overall, the cumulative results 
from a large number of studies suggest that if the 
ACE gene has any effect, it is likely to be small, 
and it is not useful as a screening marker for 
nephropathy.
 In an ongoing study on  'Role of genetic 
polymorphisms of RAAS on the reno-protective 
efﬁcacy of ACE inhibitors in patients with DN', 
we are studying various genes involved in 
RAAS, viz., ACE (I/D), angiotensinogen (AGT 
M235T) and angiotensin type I receptor genes in 
255 patients of T2DM with nephropathy. 
Genotype frequency for ACE I/D polymorphism 
was II-36.7%, ID-50.0%, DD-13.3% and allele 
frequency was found to be I-61.7% and D-
38.3%.  We found that ACE inhibitor treatment 
in patients with DN resulted in signiﬁcant 
reduction in urinary protein excretion which was 
found to be independent of ACE I/D and AGT 
M235T polymorphism (23).  
 All the patients have been put on ACE 
inhibitor therapy and are being followed-up at 
three-month intervals for a period of minimum 
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two years alongwith monitoring of albumin: 
creatinine ratio and estimated GFR to assess 
whether the gene polymorphism of RAAS can 
modulate the degree of beneﬁcial response seen 
following ACE inhibitor therapy in preventing 
the progression of DN.  
B. Genes Involved in Inﬂammatory 
Pathways 
Association of biomarkers of inﬂammation 
with the risk of chronic kidney disease in 
T2DM 
 Traditionally, DN has been considered a 
nonimmune, degenerative disease; however, in 
1991, Bohle et al (24) described the presence of 
monocytes,  macrophages,  T-cells ,  and 
ﬁbroblasts associated with the tubulo-interstitial 
changes seen in DN.  More recent reports (25, 
26) have suggested that inﬂammation may 
underlie disease progression in DN. The 
activation of Nuclear Factor kappa B (NF-kB) - 
linked regulatory pathway generally underlies 
inﬂammatory processes, and an increase in the 
nuclear translocation of NF-kB has been 
demonstra ted in  human DN (27,  28) . 
Polymorphism of NF-kB1 gene may inﬂuence 
activation / inactivation of NF-kB1 in renal cells 
which may inﬂuence urinary monocyte chemo-
attractant protein-1 (uMCP-1) levels in patients 
with DM (29, 30).
 Recent evidence has highlighted the role 
of uMCP-1 in DN and showed it as a major factor 
inﬂuencing macrophage accumulation in renal 
disease. MCP-1 is a member of the CC 
chemokine family which is produced by 
endothelial cells, vascular smooth cells, 
keratinocytes, ﬁbroblasts, mesangial cells, 
tubular epithelial cells, lymphocytes and 
monocytes/macrophages in response to a variety 
of pro-inﬂammatory stimuli. It is the strongest 
known chemotactic factor for monocytes and is 
upregulated in DN. Its expression has been 
identiﬁed in kidney diseases which involve 
signiﬁcant inﬂammation (31-34). We recruited 
150 subjects which were divided into 3 groups 
having 50 subjects in each group, viz; Group: I- 
Healthy Controls (HC), Group: II- Patients with 
T2DM without nephropathy (DM), Group: III- 
patients with T2DM with nephropathy 
(DM–CKD) in pre-dialysis stage (35) (Table 1). 
We have observed that increased level of 
inﬂammatory mediators such as TNF- α, hsCRP 
and MCP-1 may play independent as well as 
interdependent roles by inﬂuencing intracellular 
s i g n a l l i n g  w h i c h  m a y  c o n t r i b u t e  t o 
h y p e rg l y c e m i a - m e d i a t e d  i n c r e a s e  i n 
inﬂammation and lead to development and 
progression of DN (35-39).
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Table 1: Plasma levels of inﬂammatory markers in various study groups
Parameters
 
Group I ( HC)
 
(n = 50) 
Group II (DM)
 
(n = 50)  
Group III (DM -
CKD) (n = 50)   
TNF-α (pg/mL) 14.5 ± 5.2 
(13.1–16.1) 
15.3 ± 3.7  
(14.3–16.4)  
20.6 ± 3.9  
(19.5–21.8)  
hsCRP (mg/L) 0.74 ± 0.46 
(0.61–0.88) 
3.6 ± 1.5a  
(3.3–4.1)  
8.5 ± 1.7  
(8.0–9.0)  
uMCP-1 (pg/mg 
creatinine)
 
124.1 ± 46.6 
(76.3–171.7)
 
278.5 ± 125.0  
(153.1–400.8)
 
5632.7 ± 2275.8
(3351.5–8001.2)
Abbre: Group I- Healthy controls (HC), Group II- Diabetes mellitus (DM), Group III- Diabetes 
mellitus with CKD (DM-CKD).  Tumor necrosis factor-alpha (TNF- α), High sensitive C-reactive 
protein (hsCRP),Urinary monocyte chemoattractant protein-1 (uMCP-1) 
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 NF-kB1, which encodes for p105 subunit, 
that is ultimately processed to p50 subunit.  
TNF-α is a pro-inﬂammatory cytokine and both 
TNF-α and p85/p50 heterodimer (NF-kB) have 
been implicated in the pathogenesis of DN. We 
studied various genotypes (ins/ins, ins/del, 
del/del) of -94ins/del NF-kB1 gene to ﬁnd their 
association in inﬂuencing the susceptibility of 
patients with DM to develop kidney disease. We 
studied NF-kB1 gene polymorphism in a total of 
200 subjects which were divided in four groups 
of 50 subjects each: Group I-Healthy controls 
(HC), Group II- Diabetes mellitus (DM), Group 
III – DM with CKD (DM-CKD) and Group IV– 
Non-diabetic CKD (Non-DM-CKD). We 
observed that ins/del NF-kB1 genotype was 
present in highest number of subjects among all 
study groups except in patients with DM-CKD, 
where highest prevalence was of ins/ins 
genotype (Fig.1).
 We also measured uMCP levels in these 
patients and found that these levels were 
signiﬁcantly higher in patients of DM-CKD 
group as compared to HC and DM (p<0.001). 
These were also signiﬁcantly higher than non-
DM-CKD group (p<0.001). Further the patients 
with ins/ins NF-kB1 genotype had the highest 
level of uMCP suggesting the role of 
inﬂammatory pathway in pathogenesis of DN 
(Fig. 2).
Group I-Healthy controls (HC), Group II- Diabetes mellitus (DM), Group III – DM with 
CKD (DM-CKD) and Group IV – Nondiabetic CKD (Non DM-CKD)
Fig.1 :Distribution of various genotypes of-94 insertion / deletion ATTG polymorphism 
of NF-kB1 gene in study groups
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-031T/C (rs1799964) polymorphisms in the 
promoter region of TNF-α gene with plasma 
TNF-α levels among patients with T2DM with 
and without nephropathy.
 We found that the allele frequencies of       
-863C/A were 0.86/0.14 in HC group, 0.72/0.23 
in patients with T2DM and 0.84/0.16 in DN, and 
that of -1031T/C were 0.89/0.11 in HC, 
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Group I-Healthy controls (HC), Group II- Diabetes mellitus (DM), Group III- DM with 
CKD (DM-CKD) and Group IV- Non-diabetic CKD (Non DM-CKD).
Fig. 2 : Urinary MCP-1 levels in relation to different NF-kB1 genotypes in various study groups
A s s o c i a t i o n  o f  T N F - α  p r o m o t e r 
polymorphisms with plasma TNF-α levels and 
susceptibility to DN 
 TNF-α is a pro-inﬂammatory cytokine 
which plays  an important  role  in  the 
pathogenesis of various inﬂammatory diseases 
including DN. Therefore, we evaluated the 
association of -863C/A (rs1800630) and            
Table 2: Plasma TNF-  levels (pg/mL) in subjects with different TNF-  genotypesα α
Groups
 
Gp I(HC)
 
(n=100)  
Gp  II(DM)
 
(n=100)  
Gp  III(DM -
CKD)  (n=100)  
p-value
Total  14.57+5.23  15.34+3.78  20.67+3.98
a,b   
-863 CàA  
C/C  
C/A  
A/A  
 
15.38+5.45  
13.75+4.85  
9.75+1.06  
 
16.06+4.40  
14.75+2.88  
13.66+3.32  
 
21.08+3.70  
20.19+5.28  
18.62+0.17  
<0.010
F-
ratio=13.97
df=2
-1031TàC
 
T/T
 
Non T/T
 
14.31+5.16 
 
15.37+5.62 
 
15.18+3.91 
 
16.76+1.94
 
19.44+3.60 
 
23.29+3.52 
0.104
F-ratio=1
df=4.71
Values are given as mean ± SD
Non T/T= T/C+C/C
a b
Data are expressed as mean±SD. p< 0.001 vs HC; p<0.001 vs DM
Abbre: Healthy Controls – HC, Diabetes Mellitus – DM, Diabetes mellitus with chronic 
kidney disease –DM-CKD.
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Role of glutathione S-transferase M1 and T1 
gene polymorphism in patients with DN
 The glutathione S-transferases (GSTs) 
(EC 2.5.1.18) belong to a family of ubiquitous 
and multifunctional enzymes that work as one of 
the endogenous antioxidants through their 
ability to catalyze the conjugation of reduced 
GSH with electrophilic compounds and through 
their GSH peroxidase activity. Hence, reduced 
GST expression may result in diminished 
capacity of defense against OS. Interestingly, an 
earlier study has documented over-expression of 
GSTs in erythrocytes of CKD patients pointing 
to the fact that this group of enzymes might be 
involved in the pathogenesis of CKD (40). The 
mechanism by which GST polymorphism leads 
to CKD is not well-understood. In a previous 
study, Hayek et al (41) have shown that GSTT1 
null genotype is associated with increase in 
markers of lipid peroxidation among diabetics. 
 In the last few years, there has been a surge 
of reports studying the association of DN with 
Table 3: Plasma levels of oxidative stress markers in various study groups
Parameters
 
Group  I (H C)
 
(n = 50) 
Group II (DM)
 
(n = 50)  
Group III (DM -
CKD)  (n = 50)  
GSH (mg/g Hb) 3.37 ± 0.35 
(3.20–3.50) 
1.89 ± 0.06  
(1.70–1.80)  
0.90 ± 0.01  
(0.97–0.98)  
FRAP (μmol/L) 549.6 ± 49.1 
(535.6–563.6) 
409.0 ± 55.1  
(399.5–451.8)  
170.7 ± 142.3  
(166.6–231.4)  
MDA (nmol/mL) 1.48 ± 0.20 
(1.40–1.50) 
2.60 ± 0.35  
(2.50–2.70)  
5.14 ± 0.39  
(5.00–5.20)  
Abbre: Glutathione (GSH), Ferric Reducing Ability of Plasma (FRAP), Malondialdehyde (MDA)
0.95/0.05 in T2DM and 0.80/0.20 in DN. We 
found that total TNF-α levels were signiﬁcantly 
higher in patients with DM-CKD as compared to 
patients with DM without nephropathy and HC.  
The carriers of -863A allele had signiﬁcantly 
lower plasma TNF-α levels (p<0.05); however, 
no signiﬁcant association was observed between 
-1031T/C polymorphism and TNF-α levels 
(Table  2) .  We concluded that  -63C/A 
polymorphism was found to be protective; 
whereas -1031T/C allele may be associated with 
increased risk for DN in T2DM patients from 
North India.
C. Genes Involved in OS Pathway 
 Few studies have shown that OS might 
play an important role in the pathogenesis of 
CKD. The OS is also considered to be the ﬁnal 
common pathway for the development of 
diabetic complications including nephropathy. 
Several factors are responsible for the regulation 
of the balance between pro-oxidants and 
antioxidants in the body.  We measured OS 
parameters in patients of T2DM with and 
without nephropathy and compared these with 
HC. We enrolled 50 patients in each group. We 
found that antioxidant parameters like reduced 
Glutathione (GSH) and Ferric Reducing Ability 
of Plasma (FRAP) were lower in patients with 
DM and DM-CKD as compared to HC (Table 3). 
The decrease of these parameters was more 
severe in patients with DM-CKD. Further, 
oxidant stress parameters like Malondialdehyde 
(MDA) were raised in DM-CKD.
 Further,  we found that there was 
signiﬁcant correlation between markers of OS 
and inﬂammation in patients of T2DM 
with/without nephropathy in all subjects (35).  
Similarly, parameters of antioxidant activity 
such as reduced GSH and FRAP showed 
negative correlation with inﬂammatory markers 
(p < 0.001 for both).
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the genetic polymorphisms of GST. Although no 
association of GSTM1 deletion has been found 
with DN in Japanese T2DM patients (42),  
GSTT1 null genotype has been shown to be a 
risk factor for development of DN in the Chinese 
(43).  In the Korean population (44), GSTM1 
null genotype is found to be associated with 
nephropathy in T2DM patients. Ours is the ﬁrst 
study regarding the association of GST 
polymorphism with DN in Indian population. 
 We investigated the role of the GST 
polymorphisms in determining variation in 
susceptibility of individuals to CKD and to 
pinpoint the probable underlying mechanism 
(45, 46). A total of 200 subjects were enrolled 
under four study groups, viz., (i) Healthy 
subjects, n = 50; (ii) Patients of  T2DM for at 
least 10 years without any microalbuminuria or 
overt proteinuria,  n = 50; (iii) Patients of T2DM 
with nephropathy (DM-CKD), characterized by 
the presence of microalbuminuria or overt 
proteinuria, n = 50; (iv) Patients with 
nondiabetic CKD (NDM-CKD) having 
evidence of overt proteinuria and/or deranged 
renal function for more than 3 months in the 
absence of DM and any systemic or local 
infection, n = 50.  We found that GSTM1 and 
GSTT1 deletions singly or together were 
associated with lower GST levels and higher OS 
in both diabetic and nondiabetic CKD.  
Interestingly GSTT1 deletion appears to be 
associated with both diabetic and nondiabetic 
CKD irrespective of the GSTM1 status. 
Role of GSTM1 and GSTT1 genotypes in the 
development of OS in patients with DN
 In another study, we investigated whether 
the deletion of GSTM1 and GSTT1 genes are 
associated with higher OS in DN patients and the 
possible role of these polymorphisms in the 
development of DN (47, 48). We recruited 60 
patients having T2DM for more than 5 years 
with albuminuria >300 mg/day and having 
evidence of diabetic retinopathy. In all these 
patients genotypic analysis was done by using 
multiplex polymerase chain reaction (PCR). 
Various OS parameters which were studied 
included GST activity, MDA and GSH. The 
prevalence of different genetic polymorphisms 
of GST in patients with DN was: GSTM1 
positive - 32 (53.4%), GSTM1 null – 28 
(46.6%), GSTT1 positive – 27 (45%), GSTT1 
null – 33 (55%), Both null – 18 (30%) and Both 
positive – 17 (28.3%).
 Further, our study showed that double 
deletion involving GSTT1 and GSTM1 may 
result in decreased GST levels, leading to 
increased OS which may result in greater risk for 
development of DN. The levels of different OS 
parameters in various GST genotypes are given 
in Table 4.
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Table 4: Parameters of oxidative stress in different genotypes
GST (nmol/min/mg  
protein) 
MDA  
(nmol/mL)  
GSH  
(μmol/dL)  
GSTM1 null(n = 28) 0.95 ± 0.16 5.29 ± 0.89  142.1 ± 26  
GSTT1 null(n = 33) 0.98 ± 0.17 5.17 ± 1.14  143.4 ± 33.3  
Both null(n = 18) 0.87 ± 0.11
a,b
 5.84 ± 0.6 
a,b,c
 130.6 ± 34
a
 
Both positive(n = 17) 1.27 ± 0.12 4.28 ± 1.19  173.9 ± 24.5  
a
Signiﬁcantly different from both positive group at p<0.05,
b
signiﬁcantly different from GSTT1 null group at p<0.05,
c
signiﬁcantly different from GSTM1 null group at p<0.05
(ANOVA with Tukey SD as post-hoc test)
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Table 5:  Plasma levels of oxidant-antioxidant markers in various study groups
Parameters Group  I 
(HC) 
(n=100) 
Group  II 
(DM)  
(n=100)  
Group  III 
(DM-CKD)  
(n=100)  
GSH (mg/g Hb) 
GST (nmol/min )
3.2±0.2 
(3.0-3.9) 
6.3±0.6 
(4.1-7.8) 
1.7±0.2
a,c  
(1.0-1.9)  
8.6±0.5
a,c
 
(7.6-10.2)  
0.85±0.1
a,b  
(0.12-1.1)  
7.5±0.3
a,b
 
(6.25-8.1)  
MDA (nmol/mL) 1.5±0.3 
(0.9-2.2) 
2.5±0.3
a,c  
(2.0-3.1)  
5.2±0.5
a,b  
(4.3-6.8)  
FRAP (µmol/L) 542.9±54.0 
(425-660) 
404.8±48.4
a,c
 
(300.8-494.9)  
163±40.2
a,b
 
(95.5-335)  
Data are expressed as mean±SD.Group I- Healthy control (HC); Group II- Type 2 diabetes 
mellitus without nephropathy (DM) Group III- Diabetes mellitus with CKD (DM-CKD)
a
signiﬁcantly different from healthy control at p<0.05, 
b
signiﬁcantly different from diabetic patients without nephropathy at p<0.05, 
c
signiﬁcantly different from diabetic patients with nephropathy at p<0.05.
D. Genes Involved in Cytoprotective 
Pathway 
 NAD(P)H quinone oxidoreductase 1 
(NQO1) plays a prominent role in maintaining 
cellular homeostasis and is an essential 
component of the antioxidant defense system.  It 
catalyzes metabolic detoxiﬁcation of quinines 
and protects cells against chemical induced OS. 
Expression of NQO1 increases in response to 
oxidant and electrophilic radicals to counteract 
OS, and in fact, it is a kind of cytoprotective 
defense mechanism for cells.  
GST levels in patients with T2DM with and 
without nephropathy
 Hyperglycemia induced OS is implicated 
as a contributor to the onset and progression of 
T2DM and its complications like DN. GST is 
primarily involved in the neutralization of 
Reactive Oxygen Species (ROS) by enzymatic 
conjugation with the scavenger peptide GSH 
(49-51).  In another study, we evaluated the role 
of GST along with OS markers and their 
correlation in patients with T2DM with and 
without nephropathy.  We have recruited 300 
study subjects divided into three groups of 100 
each: HC, DM and DM-CKD. Plasma GST, 
MDA, reduced GSH levels and FRAP were 
estimated spectrophotometrically.
 GST levels were found to be raised in the 
patient groups in comparison to HC, however, 
the highest signiﬁcant levels were seen in T2DM 
as compared to DM-CKD (p<0.05). Other 
oxidant and antioxidant markers are shown in 
Table 5. The antioxidant parameters including 
GSH and FRAP were signiﬁcantly lower in DN 
as compared to T2DM and HC (p<0.05). Higher 
lipid peroxidation was seen in patients of DM-
CKD as MDA levels were signiﬁcantly raised 
when compared to T2DM and HC (p<0.05). We 
found negative correlation between HbA1c and 
GSH (r= -0.942, p<0.01) and FRAP (r= -0.854, 
p<0.01). A positive association was observed 
between HbA1c and GST (r= 0.606, p<0.01) and 
MDA (r= 0.839, p<0.01); however, a signiﬁcant 
negative correlation between GST activity and 
GSH levels (r= -0.530, p<0.01) and FRAP (r=    
-0.294, p<0.01) was observed. GST activity was 
positively correlated with MDA levels (r= 0.253, 
p<0.01).
O.P. Kalra
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Table 6. NQO1 levels in plasma (ng/mL) in context of different NQO1 genotypes
Groups Group  I 
(HC) 
(n=200) 
Group  II 
(DM)  
(n=200)  
Group  III  
(DN)  
(n=200)  
 
p-value  
NQO1*1/*1 
NQO1*1/*2 
NQO1*2/*2
 
4.16±0.47  
1.9±0.46 
a
 
0.62±0.06
a,b
 
31.36±1.19  
25.99±0.81
a
 
20.32±1.28
a,b
 
15.51±0.78  
11.06±0.67
a
 
7.43±0.85
a,b
 
 
<0.05  
 
Plasma NQO1 levels are given as mean±SD.  Group I- Healthy Control (HC), 
Group II- Type 2 Diabetes Mellitus without complications (DM), 
Group III- Diabetic Nephropathy (DN)
a
signiﬁcantly different from homozygous NQO1*1/*1 in study groups at p<0.05
b
signiﬁcantly different from heterozygous NQO1*1/*2 in study groups at p<0.05
 Among DN and T2DM patients, the OR 
for the development of DN was 1.72-fold higher 
in T2DM patients carrying the NQO1*2/*2 
genotype than in those carrying NQO1*1/*1 or 
NQO1*1/*2 genotypes (95% CI=1.133 to 
2.600). A signiﬁcant association was observed 
for NQO1*2 polymorphism in patients of T2DM 
when compared to HC (OR=6.638, 95% 
CI=1.427–30.876,  p=0.016) .  NQO1*2 
polymorphism was shown to be associated with 
an increased risk of DN in comparison to HC 
(OR=22.00, 95% CI=5.075-95.376, p=0.000). 
Therefore, it may be concluded that NQO1*2 
allele may increase the risk for developing DN in 
T2DM patients as well as HC.
E. Genes Involved in Nitric Oxide (NO) 
Pathway 
 NO is a major regulator of renal 
hemodynamics, its production being catalysed 
by endothelial nitric oxide synthase (eNOS). 
Reduction in the generation of NO acts as a 
deteriorating factor for progressive renal 
disease. Polymorphisms in the eNOS gene may 
alter its expression, thus affecting the production 
of NO. Familial clustering DN points to a role of 
genetic factors in the pathogenesis of renal 
disease.
Genetic association of NAD(P)H Quinone 
Oxidoreductase (NQO1*2) polymorphism with 
NQO1 levels and risk of DN
 NQO1 catalyzes reactions having cyto-
protective effect against redox cycling and OS. 
A single base polymorphism (C/T) at nucleotide 
609 of NQO1 gene impairs the stability and 
function of its protein (52-54). Its role in the 
development of DN has not been studied earlier. 
We evaluated the association of NQO1*2 
(rs1800566) polymorphism with plasma NQO1 
activity and DN. We have  screened 600 study 
subjects including healthy controls (HC), Type 2 
diabetes mellitus without complications 
(T2DM) and diabetic nephropathy (DN): (200 
subjects in  each group) for studying NQO1*2 
gene polymorphism using the PCR-RFLP. 
Plasma NQO1 activity was measured by ELISA.
 NQO1 activity was signiﬁcantly increased 
in both the diseased groups, however, it was 
highest in T2DM patients (8 times) followed by 
DN (3.5 times) vs HC group. Correlation 
between NQO1*2 polymorphism and NQO1 
activity in plasma was studied. It was found that 
in all the genotypes, NQO1 activity was highest 
in T2DM vs DN as compared to HC where it was 
the lowest; however, NQO1*1 allele was 
associated with higher NQO1 activity and 
NQO1*2 allele with lower activity of NQO1. 
SNP NQO1*2 is a functional polymorphism 
since it was seen to inﬂuence plasma NQO1 
activity and NQO1*2 allele was associated with 
decreased plasma NQO1 activity (p<0.01) in 
T2DM, DN and HC (Table 6). 
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bind to speciﬁc RAGE which is expressed in 
many of the cell types such as endothelial cells, 
monocytes and lymphocytes, including β cells of 
pancreas (60-62). The gene for RAGE is located 
on the chromosome 6p21.3 near the HLA locus, 
and at least 30 polymorphisms have been 
identiﬁed of which 9 are in promoter region, 11 
in exon region and 10 in intron region. 
 Three polymorphisms of RAGE gene 
namely -374T/A, -429T/C and Gly82Ser have 
been widely studied with regard to the 
development of diabetic complications in 
different populations all over the world. We 
investigated the association of -374T/A,            
- 4 2 9 T / C  a n d  G l y 8 2 S e r  R A G E  g e n e 
polymorphisms and their haplotypes with 
vascular complications in T2DM patients which 
may help in identifying DM patients predisposed 
to possible micro- and macrovascular 
complications as a result of their genetic makeup 
(63). A total of 427 patients of T2DM with 
disease duration > 5 years were enrolled in this 
study. These patients were divided into three 
groups. The ﬁrst group referred to as 'DM' 
comprised of 140 T2DM subjects without any 
vascular complications. The second group 
referred to as 'DM-micro' consisted of 152 
T 2 D M  s u b j e c t s  w i t h  m i c r o v a s c u l a r 
complications (retinopathy and nephropathy). 
The third group referred to as 'DM-macro' 
consisted of 135 T2DM subjects with 
macrovascular complications. In addition, 176 
HCs were enrolled in the study. 
 
 We found that -429T/C and Gly82Ser 
RAGE polymorphisms were signiﬁcantly 
a s s o c i a t e d  w i t h  t h e  d e v e l o p m e n t  o f 
macrovascular and microvascular complications 
respectively in T2DM subjects  while -374A 
allele showed reduced risk towards the 
development of macrovascular complications. 
Further, -429T/C, -374T/A and Gly82Ser 
haplotype analysis revealed association of CTG 
haplotype with development of macrovascular 
complications while haplotype TAG was 
observed to be signiﬁcantly protective towards 
development of macrovascular complications in 
 Hey et al published a meta-analysis of 24 
studies and analysed the polymorphisms of 
eNOS genes (4b/a,G894T and T786C) 
associated with DN (55). It was found that 4b/a 
and G894T polymorphisms in the eNOS gene 
were associated with susceptibility to DN in 
Asian populations, but not in Caucasian 
populations. A meta-analysis of 8 studies 
performed by Zhou et al evaluated the 
association of G894T gene polymorphism alone 
with DN susceptibility (56). These studies 
included 850 cases and 1254 controls. In the 
Asian population, the average frequency of T-
allele was 19.19% in DN patients and 8.68% in 
controls. A signiﬁcant association was observed 
between the presence of T-allele and DN risk in 
the overall population. 
 We  s t u d i e d  t h e  e N O S  G 8 9 4 T 
polymorphism in patients of diabetes with and 
without nephropathy and measured the serum 
NO levels in these patients and compared them 
in the HCs.  It was found that patients with DN 
add lowest levels of NO (22.02±16.18 µM) as 
compared to diabetics without nephropathy 
(63.86 ± 29.49 µM) and HC (38.42 ± 13.71 µM) 
(p< 0.001).  Further a positive association was 
observed between eNOS G894T polymorphism 
as the frequency of TT genotype as well as that of 
mutant T allele was increased in patients with 
DN as compared to diabetics  without 
nephropathy and HCs (57). 
F. Genes Involved in Advanced Glycation 
End-products (AGE) and its Receptor 
(RAGE)  Interaction 
Association of RAGE gene polymorphism with 
vascular complications in patients with T2DM
 Hyperglycemia associated with DM 
stimulates non-enzymatic glycation and 
oxidation of proteins and lipids leading to 
enhanced formation of AGEs. There is growing 
evidence that production and accumulation of 
AGEs is involved in the initiation and 
development of micro- and macrovascular 
complications observed in DM (58, 59). AGEs 
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T2DM subjects (OR = 0.617, p = 0.0202). 
G. Gene Expression Studies 
Role of AGE-RAGE expression in diabetic 
vascular complications
 Interaction of AGE with its receptor 
RAGE transduces multiple signals such as 
NAD(P)H oxidase, Mitogen-Activated Protein 
(MAP) kinases, extracellular signal regulated 
kinases, GTPase, etc. (64, 65).  Activation of 
NAD(P)H oxidase causes enhanced Reactive 
Oxygen Species (ROS) generation which may 
lead to peroxidation and glycoxidation reactions 
that results in Protein Carbonyl (PCO) 
formation, Advanced Oxidation Protein 
Products (AOPP) generation and lipid 
peroxidation. These OS markers have been 
shown to be enhanced signiﬁcantly in diabetic 
patients (66, 67).  On the other hand, activation 
of kinases and GTPases causes activation of 
nuclear transcription factor including NF-kB 
which transcribes its target genes such as 
Vascular Cell Adhesion Molecule – 1 (VCAM-
1), E-selectin and pro-inﬂammatory cytokines.
 AGE-RAGE interaction is one of the 
mediators of vascular complications in DM; 
however,  factors  that  possibly induce 
exaggerated AGE-RAGE interaction are not 
well known. RAGE is usually expressed at low 
levels in adults. Enhanced AGE-RAGE 
interaction possibly requires increased 
expression of RAGE. In various diseased states 
such as CVD, diabetes, inﬂammation, etc., there 
is higher expression of RAGE; however, 
conditions and factors that may induce RAGE 
expression particularly in T2DM have not been 
elucidated. 
 Since AGE formation is an integral 
phenomenon in T2DM, we investigated the 
dependence of RAGE expression on circulating 
AGE level and have examined the outcome of 
AGE-RAGE interaction by measurement of OS 
status in those patients (68). We recruited 75 
patients of T2DM with disease duration > 5 
years for this study. These patients were divided 
into three groups. The ﬁrst group referred to as 
'DM' comprised of 25 T2DM subjects without 
any vascular complications. The second group 
referred to as 'DM-micro' consisted of 25 T2DM 
subjects with microvascular complications 
(retinopathy and nephropathy). The third group 
referred to as 'DM-macro' consisted of 25 T2DM 
subjects with macrovascular complications. In 
addition, 25 HCs were also enrolled in the study 
by voluntary participation. 
 We observed that serum AGEs levels were 
signiﬁcantly higher in diabetic patients having 
vascular complications as compared to T2DM 
without complications (p < 0.01) (Table 7). 
RAGE m-RNA expression level in PBMCs 
assayed by quantitative real time PCR was four 
times higher in diabetic subjects without 
vascular complications while DM patients 
having microvascular or macrovascular 
complications showed 12 fold and 8 fold higher 
RAGE m-RNA expression, respectively, 
compared to HCs. Further, circulating AGEs 
levels showed signiﬁcant positive correlation 
with RAGE m-RNA expression and OS markers 
(Fig.3).
H.  Epigenetic Studies 
 Epigenetics is the study of inherital 
changes in phenotype or gene expression caused 
by mechanisms other than changes in the 
underlying DNA sequence; therefore, non-
genetic factors cause the organism's genes to 
behave differently.  There is some evidence to 
suggest the role of epigenetic factors in the 
complex interplay between genes and 
environment.  Epigenetic mechanisms include 
DNA methylation, histone modiﬁcation and 
microRNAs.  Few studies have suggested that 
hyperglycemia may induce epigenetic changes 
of pro-inﬂammatory genes, which subsequently 
regulate gene expression and thereby the 
development of vascular complications (69, 70);  
however, improved glycemic control for 3 – 5 
years at a later stage in diabetic patients did not 
reduce the risk of macrovascular complications 
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Fig. 3:  Circulating AGEs shows signiﬁcant positive correlation with RAGE m-RNA 
expression among diabetic subjects. (A) Relationship between circulating AGEs and 
RAGE m-RNA expression among diabetic subjects. (B) Relationship between 
ﬂuorescent AGEs and RAGE m-RNA expression among diabetic 
subjects. Correlation analysis was performed using Pearson's coefﬁcient.
Table 7. Serum AGE levels and oxidative stress markers in 
diabetic patients and healthy subjects
Parameters
 
DM
 
DM-micro
 
DM-macro
 
Healthy 
subjects
AGE ELISA (µg/mL)
 
1.4±0.54
 
3.4±0.95
a
 
2.32±0.88
a
 
1.12±0.38
AGE-F (AU)
 
1.97±0.43
 
2.68±0.39
a
 
2.50±0.32
a
 
1.87±0.29
MDA (nmol/mL)
 
0.43±0.15
 
0.76±0.22
a
 
0.81±0.37
a
 
0.26±0.06
PCO (nmol/mg protein)
 
1.6±0.43
 
2.8±1.0
a
 
3.0±0.72
a
 
1.4±0.43
AOPP (µmol/L of 
chloramines T-
 
equivalent)
 
103±27.2
 
163±42.2
a
 
206±54.2
a
 
85±21.9
Data are presented as mean ± SD. 
Comparison between the groups was performed with one-way ANOVA and followed by post hoc 
a
Tukey's analysis. p< 0.05 compared with controls and DM group.
Advanced glycation end-product (AGE), Malonyldialdehyde (MDA), Protein carbonyl (PCO),
Advanced oxidation protein product (AOPP), Diabetes mellitus (DM), Diabetes mellitus
with microvascular complications (DM-micro), Diabetes mellitus with 
macrovascular complications (DM-macro).
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diabetic patients. We found signiﬁcant 
association of -429T/C and Gly82Ser RAGE 
polymorphisms with the development of 
m a c r o v a s c u l a r  a n d  m i c r o v a s c u l a r 
complications, respectively in T2DM subjects 
while -374A allele showed reduced risk towards 
t h e  d e v e l o p m e n t  o f  m a c r o v a s c u l a r 
complications.  Further, we have observed that 
AGE-mediated exacerbation of RAGE 
expression may contribute to OS generation that 
plays a key role in pathogenesis of various 
vascular complications in DM. 
 To conclude, polymorphisms of various 
genes involved in RAAS, inﬂammatory, oxidant 
stress, cytoprotective and nitrous oxide 
pathways may inﬂuence the levels of various 
cy tokines  and  in t race l lu la r  s igna l ing 
mechan i sms ,  the reby  inﬂuenc ing  the 
susceptibility of patients with DM for 
development of kidney disease.  In addition, 
r a i s e d  A G E  a n d  A O P P  l e v e l s  a n d 
polymorphisms of RAGE and enhanced RAGE 
mRNA expression may adversely inﬂuence ﬁnal 
common pathway through oxidant stress 
mechanisms, and thereby determine the 
development  of  microvascular  and/or 
macrovascular complications in patients with 
DM.
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Key Findings and Summary 
 There is enough evidence from our studies 
to support the hypothesis that genetic factors 
play a crucial role in determining susceptibility 
of patients with DM for development of 
nephropathy. We have found that D allele of 
ACE gene acts as risk factor for the development 
of nephropathy in patients with T2DM as well as 
for nondiabetic CKD; whereas I allele of ACE 
gene was protective in nature. Further, whether 
ACE gene polymorphism can modulate the 
degree of beneﬁcial reno-protective effect 
following ACE inhibitor therapy is currently 
under investigation in our laboratory. We have 
found that OS plays a signiﬁcant role in the 
development of DN, and that GSTT1 and/or 
GSTM1 null genotypes are associated with 
higher OS in patients with DN. In addition, we 
also found that increased levels of inﬂammatory 
mediators i.e. TNF-α, hsCRP and uMCP-1 play 
an independent as well as interdependent roles, 
via several signaling pathways contributing to 
hyperglycemia-mediated increase in OS. We 
have shown that genetic polymorphism of NF-
kB gene and TNF-α gene plays a signiﬁcant role 
in determining serum level of various 
inﬂammatory markers and OS parameters. An 
i n c r ea s e  i n  O S  may  f u r t h e r  amp l i f y 
inﬂammation, thus setting up a vicious cycle. 
Therefore, inﬂammation interlinked with OS 
may be major mechanisms in the pathogenesis 
and progression of nephropathy in susceptible 
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